Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of XG005 in Healthy Volunteers
NCT04499209Phase 1Completed
- Sponsor
- Xgene Pharmaceutical Inc.
- Start
- Oct 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pregabalin naproxencarbil in pain (3 arms), sponsored by Xgene Pharmaceutical Inc. Primary endpoints: Maximum concentration, Time to maximum concentration and 6 more. Started Oct 2017; status: completed.
02
Drugs
pregabalin naproxencarbil
03
Conditions
pain
Beyond the preview
Go deeper on NCT04499209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04499209.